Clinical Trial

Alterations in Mast Cell and Macrophage Infiltration, as Well as Micro Vessel Density

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
Obesity is a global health problem that has reached epidemic proportions, affecting more than one billion people worldwide and significantly increasing the risk of multiple comorbidities, including type 2 diabetes, cardiovascular diseases, and cancer (World Health Organization, 2024). Increasing evidence suggests that chronic low-grade inflammation associated with obesity plays a critical role in the development of obesity-related malignancies, including gastric cancer. Adipose tissue dysfunction in obesity leads to the recruitment and activation of various immune cells, such as macrophages and mast cells, which contribute to a pro-inflammatory microenvironment through the release of cytokines, growth factors, and angiogenic mediators.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-30
Trial Details
NCT Number NCT07448896
Lead Sponsor General Committee of Teaching Hospitals and Institutes, Egypt
Conditions Obesity
Enrollment 100 participants
Start Date 2026-04-15
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-29